Skip to content

Gastric cancer patients' survival with neoadjuvant chemotherapy versus direct surgery

Mar 2026 · Caspian Journal of Internal Medicine · Vol 17, pp. 334 - 346 · 0 citations · 31 references
Medicine

TL;DR

NAC was effective in increasing survival in the groups with lymph o vascular invasion, higher stage and all pathologic groups, but age, type of surgery, number of positive lymph nodes, positive margin after surgery were not effective interfering with survival in both groups.

Abstract

Background: Despite these theoretical advantages, there is still a lack of evidence to answer whether NeoAdjuvant Chemotherapy (NAC) can further improve the survival of Locally Advanced Gastric Cancer (LAGC) patients on the basis of Adjuvant Chemotherapy (AC) following curative gastrectomy. The present research assessed the 36-month survival of gastric cancer patients treated in our center with and without NAC and over-all 36-month survival. Methods: The present research assessed the 36-month survival of gastric cancer patients treated in our center with and without NAC and over-all 36-month survival. 79 patients entered this study, of whom 64 received NAC and 15 underwent direct surgery. Results: Generally, the three-year survival rate in the groups was statistically different based on the Wilcoxon test (P 0.004). NAC was effective in increasing survival in the groups with lymph o vascular invasion, higher stage and all pathologic groups. However, age, type of surgery (TG vs DG), number of positive lymph nodes, and positive margin after surgery were not effective in interfering with survival in both groups. Neoadjuvant chemotherapy can positively increase OS and DFS in locally advanced gastric cancer. NAC was effective in increasing survival in the groups with lymph o vascular invasion, higher stage and all pathologic groups. Conclusion: Considering the similar results in previous studies, larger prospective studies with accurate information can effectively achieve definitive results. However, age, type of surgery (TG vs DG), number of positive lymph nodes, positive margin after surgery were not effective interfering with survival in both groups.

View source

Similar papers

Open access Oct 2026

Re-evaluating the Role of Adjuvant Chemotherapy after Neoadjuvant Therapy in Resected Gastric Cancer.

BACKGROUND Perioperative chemotherapy is standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients with resectab...

Aravind Sreeram, Celine Yeh, N. Toumbacaris et al. · 0 citations
Sep 2026

Assessing the efficacy of adjuvant chemotherapy in patients with T3N0 gastric cancer.

In patients with T3N0 stage after surgery, the chemotherapy group demonstrated OS and RFS similar to surgery-only group, and the benefit of adjuvant chemotherapy in patients with T3N0 gastric cancer remains uncertain.

Ki-Yoon Kim, Jawon Hwang, Sung Hyun Park et al. · 0 citations
Sep 2026

Association of Adjuvant Immunotherapy With Survival Outcomes Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Immunochemotherapy: A Propensity Score-Matched Cohort Study.

BACKGROUND For patients with locally advanced gastric cancer (LAGC) who have received neoadjuvant immunochemotherapy (NAIC), it has been recognized that adjuvant chemotherapy after operation is indispensable for the majority of cases; nevertheless, whether additional postoperative adjuvant immunotherapy is needed is st...

Wei-Jun Zhang, Zhuo-Yu Jia, Qi Liu et al. · 0 citations
Open access Aug 2026

Prognostic Value of Tumor Regression Grade in Geriatric Patients with Locally Advanced Gastric Adenocarcinoma

Background and Objectives: Tumor regression grade (TRG) in gastric cancer patients treated with neoadjuvant/perioperative chemotherapy is increasingly recognized as an important indicator of treatment efficacy and long-term prognosis. However, in geriatric patients, data on neoadjuvant therapy and on the relationship b...

Didar Şenocak, Bunyamin Guney, M. Karakullukcu et al. · 0 citations
Sep 2026

Exploring the role of adjuvant chemotherapy in older patients with early-stage pancreatic adenocarcinoma.

INTRODUCTION The survival advantage of adjuvant chemotherapy (AC) for older patients with stage I pancreatic ductal adenocarcinoma (PDAC) is unclear, yet it is a mainstay of treatment. This study aims to explore the association of AC with overall survival (OS) in patients of various age groups. MATERIALS AND METHODS...

Madeline Farrar, Nupur Shridhar, Mason D. Stillman et al. · 0 citations
Open access Aug 2026

Effects of Chemotherapy and Chemoradiotherapy on Survival and Toxicity in Locally Advanced Unresectable Pancreatic Cancer

The optimal treatment for locally advanced, unresectable pancreatic cancer remains controversial. This study aimed to compare the effects of chemotherapy and chemoradiotherapy on survival and toxicity in patients with locally advanced, unresectable pancreatic cancer. A total of 59 patients were retrospectively analyzed...

Gülen Doğan, E. Kurt · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.